First-in-human evaluation of a biological regenerative vascular conduit for hemodialysis access
The Journal of Vascular Access · 2024-07 · 25 (4) · 1271-1278
DOI: 10.1177/11297298221147709 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Vascular Access, online erschienen am 09.03.2023. Verfasst von Adrian Ebner und 14 weiteren Autor:innen. Beteiligte Einrichtung: Sanatorio Italiano, Asuncion, Paraguay. Hauptthemen laut MEDLINE: Renal Dialysis, Arteriovenous Shunt, Surgical, Blood Vessel Prosthesis Implantation, Vascular Patency. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 18 Literaturangaben.
Abstract (Originalsprache)
Introduction
The long-term survival and low complication rate of autogenous fistulas for hemodialysis access is often offset by early thrombosis and slow or failed maturation leading to the use of central venous catheters. A regenerative material may have the potential to overcome these limitations. A completely biological acellular vascular conduit was investigated in this first-in-human clinical study.
Methods
With approval of the ethics board and patients’ informed consent, five subjects were enrolled based on predetermined inclusion criteria. Five patients underwent implant of a novel acellular, biological tissue conduit (TRUE AVC™) in the upper arm in a curved configuration between brachial artery and axillary vein. After maturation, standard dialysis was commenced through the new access. Patients were followed up to 26 weeks with ultrasound and physical exam. Serum samples were evaluated for an immune response to the novel allogeneic human tissue implant.
Results
This new tissue conduit handled well surgically, with properties similar to that of native human vein. Post procedure conduit flow was excellent in all cases, averaging 1098 ± 388 ml/min at week 4 and remaining stable through 1248 ± 355 ml/min at 26 weeks. Surgical site healing was normal with no edema or erythema by week 4. Six-month primary assisted patency was 80% and secondary patency was 100%. Prescribed dialysis was successfully delivered without infection, and there was no significant change in conduit diameter. Serum testing showed no increase in PRA or IgG specific to the TRUE AVC. One implant required intervention at 5 months with thrombectomy and covered stent procedure.
Conclusion
This first-in-human 6-month study with favorable patency and low complication rate establishes the initial safety and feasibility of this novel biological tissue conduit for dialysis access in patients with end-stage kidney disease. Its mechanical durability and lack of immune response establishes TRUE AVC as a potential regenerative material for clinical use.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Sanatorio Italiano, Asuncion, Paraguay.
- Laboratorio Curie, Asuncion, Paraguay.
- Vascudyne, Inc., St. Paul, MN, USA.
- University of Minnesota, Minneapolis, MN, USA.
- Rush University, Chicago, IL, USA.
ORCID-Profile: Zeeshan Syedain, Haimanot Wasse
Zitieren
APA
Ebner, A., Gallo, S., Castellano, J., Filartiga, M., Haarstad, A., Pries, C., Gahlbeck, K., McMahon, M., Herrera, C., Avila, M., Schankereli, K., Murphy, R., Stenoien, M., Syedain, Z., & Wasse, H. (2024). First-in-human evaluation of a biological regenerative vascular conduit for hemodialysis access. The Journal of Vascular Access, 25(4), 1271-1278. https://doi.org/10.1177/11297298221147709
Vancouver
Ebner A, Gallo S, Castellano J, Filartiga M, Haarstad A, Pries C, et al. First-in-human evaluation of a biological regenerative vascular conduit for hemodialysis access. The Journal of Vascular Access. 2024;25(4):1271-1278. doi:10.1177/11297298221147709
BibTeX
@article{Ebner2024,
author = {Ebner, Adrian and Gallo, Santiago and Castellano, Juan and Filartiga, Maria and Haarstad, Allie and Pries, Cory and Gahlbeck, Kate and McMahon, Mariah and Herrera, Camila and Avila, Martha and Schankereli, Kem and Murphy, Rick and Stenoien, Mark and Syedain, Zeeshan and Wasse, Haimanot},
title = {First-in-human evaluation of a biological regenerative vascular conduit for hemodialysis access},
journal = {The Journal of Vascular Access},
year = {2024},
volume = {25},
number = {4},
pages = {1271--1278},
doi = {10.1177/11297298221147709}
}
EUVIMED